Expert Analysis

Myelodysplastic Syndromes

Source: CCO Independent Conference Coverage of the American Society of Hematology 2007 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Myelodysplastic Syndromes

Program Director: Roy A. Beveridge, MD

Faculty:

Alan F. List, MD
Azra Raza, MD
Lewis Silverman, MD

Moderator: Allen S. Yang, MD, PhD

CME CREDIT INFORMATION

Release Date: 02/22/08

Expiration Date: 02/21/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing CE credits

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe key studies of hypomethylating agents for the treatment of myelodysplastic syndromes
Explain the significance of the deletion 5q syndrome and the impact it has on treatment choices
Discuss the role of iron chelation in the treatment of patients with transfusion-dependent myelodysplastic syndromes
Review studies of novel therapeutics for treatment and supportive care of myelodysplastic syndromes
Identify candidate genes involved in the pathogenesis of 5q- syndrome

Topics covered include:

Azacitidine in First-Line Treatments for High-Risk MDS
Alternative Administration of Azacitidine Allows for Elimination of Weekend Dosing
Use of Low-Dose Decitabine in Patients With Intermediate- and High-Risk MDS
Lenalidomide Therapy for MDS Patients With Deletion 5q
Investigation of the Cause of 5q- Syndrome
Molecular Targets of Lenalidomide Therapy in Deletion 5q MDS
Dose Escalation Trial of the Investigational Glutathione S1 Transferase Inhibitor TLK199
Phase I/II Study of Romiplostim (AMG 531) in Patients With Low-Risk and Intermediate-1–Risk MDS
Use of Iron Chelation Among Transfusion-Dependent Patients With MDS
Safety and Efficacy of Deferasirox in Patients With Transfusion-Dependent MDS

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.